Euronext Paris

bonyf Advances to Phase 2 in Development of Alginate-Organic Denture Fixative Cream

Retrieved on: 
Mercredi, avril 10, 2024
Cream, Euronext Paris, Safety, Marketing, Research, Organic, Mnemonic, Alginic acid, Risk management

Throughout Phase 1, bonyf's dedicated team of researchers and scientists conducted rigorous testing to evaluate the performance and safety of the Alginate-Organic Denture Fixative Cream.

Key Points: 
  • Throughout Phase 1, bonyf's dedicated team of researchers and scientists conducted rigorous testing to evaluate the performance and safety of the Alginate-Organic Denture Fixative Cream.
  • "We are excited to enter Phase 2 of development for our Alginate-Organic Denture Fixative Cream", said Jean-Pierre Bogaert, CEO at bonyf.
  • The Alginate-Organic Denture Fixative Cream represents a significant advancement in denture care, harnessing the natural benefits of Alginate and Organic ingredients to deliver superior grip and comfort for denture wearers.
  • As bonyf progresses through Phase 2, the company remains dedicated to transparency and excellence in its research and development efforts.

EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Retrieved on: 
Mercredi, avril 10, 2024
EST, Q&A, Patient, Webcast, Document, Annual report, Euronext Paris, AMF, Therapy, Cryptocurrency

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Key Points: 
  • Abivax publishes financial reports with the French and U.S. securities regulatory agencies
    The issuer is solely responsible for the content of this announcement.
  • The Universal Registration Document includes the 2023 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.
  • To participate and ask questions during the webcast, please register via the Abivax website .

Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting

Retrieved on: 
Mardi, avril 9, 2024
Euronext Paris, Proxy, Internet

Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary general meeting convened on first call on Wednesday April 10, 2024, will not be held as the quorum required by law has not been reached.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary general meeting convened on first call on Wednesday April 10, 2024, will not be held as the quorum required by law has not been reached.
  • The shareholders of Nicox are thus convened on second call for an Ordinary and Extraordinary general meeting on the same resolutions and the same agenda on Monday May 6 at 2:30 pm CET in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.
  • Shareholders may vote by proxy, by internet or by attending the Ordinary and Extraordinary shareholder meeting in person.
  • The proxy forms sent by correspondence, or the electronic votes received for the Ordinary and Extraordinary general meeting initially planned on April 10, 2024 remain valid for the Ordinary and Extraordinary general meeting of May 6, 2024.

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Retrieved on: 
Mardi, avril 9, 2024
PDT, Chemoradiotherapy, Head, Disease, Intelligence, Patient, Neoplasm, Health care, Cancer, AI, AACR, NEC, Curie Institute (Paris), Euronext Paris, Poster, Corporation, Neck, Vaccine

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.

Key Points: 
  • Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.
  • These data are highlighted in the AACR press conference being held today and in a poster presentation which will take place tomorrow, April 10, at 9:00 a.m. PDT.
  • Key findings of the poster include:
    All 16 patients who received TG4050 are disease free after a median 18.6-month follow-up.
  • TG4050 is now starting to show a potential benefit for head and neck cancer patients at high risk of relapse.

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Retrieved on: 
Vendredi, avril 5, 2024
EST, Q&A, Patient, Webcast, Document, Annual report, Euronext Paris, AMF, Therapy

The Universal Registration Document includes the 2023 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

Key Points: 
  • The Universal Registration Document includes the 2023 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.
  • To participate and ask questions during the webcast, please register via the Abivax website .

AKWEL : CURRENT OPERATING INCOME UP 64% TO €61M

Retrieved on: 
Jeudi, avril 4, 2024
Euronext Paris, Carbon, Annual, Water, Table tennis rubber, Investment, Environment, WCR, CSR, Pharmaceutical industry

Positive business developments and the gradual impact of some price rises have helped to improve current operating profit.

Key Points: 
  • Positive business developments and the gradual impact of some price rises have helped to improve current operating profit.
  • A provision of €9.4m associated with the exceptional costs of restructuring the Gournay (France) site weighed on the operating income.
  • With investments up sharply to €59.3m, AKWEL has generated free cash flow of €4.6m and net cash position of €105m, compared with €113.7m at the end of 2022.
  • Operating in 20 countries across 5 continents, AKWEL employs 9,600 people worldwide.

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Retrieved on: 
Mercredi, avril 3, 2024
Euronext Paris, AMF, Fatty liver disease, Annual report

Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that it had filed its 2023 Universal Registration Document for the year ended December 31, 2023, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” (“AMF”) and its 2023 Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”).

Key Points: 
  • Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that it had filed its 2023 Universal Registration Document for the year ended December 31, 2023, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” (“AMF”) and its 2023 Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”).
  • These documents can be accessed on the “Investors” section of the Company’s corporate website ( www.inventivapharma.com ).
  • In addition, the 2023 Universal Registration Document is available on the website of the AMF ( www.amf-france.org ) and the 2023 Annual Report on Form 20-F is also available on the website of

Inventiva announces the nomination of Andre Turenne as Director

Retrieved on: 
Jeudi, mars 28, 2024
Business, Kalamazoo College, Tuck School of Business, Business development, Therapy, Fatty liver disease, Euronext Paris, NASH, Match point, Atlas Venture, Management

Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: “We are extremely pleased that our Board of Directors has proposed the appointment of Andre.

Key Points: 
  • Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: “We are extremely pleased that our Board of Directors has proposed the appointment of Andre.
  • We look forward to welcoming Andre as the newest member of our Board of Directors.”
    Mr. Turenne has more than 20 years of global experience in the pharmaceutical industry.
  • Prior to joining Matchpoint, Mr. Turenne served as President and Chief Executive Officer of Voyager Therapeutics.
  • Andre Turenne, non-executive director nominee: “I am delighted to have the opportunity to join the Board of Directors of Inventiva, which is at a pivotal stage in its clinical program in NASH.

Inventiva reports its 2023 full-year results

Retrieved on: 
Mercredi, mars 27, 2024
DSM-IV codes, NMPA, Acceleration, Partnership, Patient, Income tax, G&A, BofA Securities, MASH, Equity, SUSAR, IND, Marketing, Bank statement, IRB, Clinical trial, Investigational New Drug, European Investment Bank, Fatty liver disease, Type 2 diabetes, T2D, Euronext Paris, EIB, Phase, Optimism, NAFLD, Sino Biopharmaceutical Limited, Pharmaceutical industry

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.

Key Points: 
  • Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.
  • R&D expenses for the fiscal year ended December 31, 2023, amounted to (€110.0) million compared to (€60.5) million in 2022.
  • Net financial income was (€5.1) million for the fiscal year ended December 31, 2023, compared to €2.8 million in 2022.
  • Income tax amounted to (€0.6) million for the 2023 fiscal year, compared to €0 million for 2022.

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Retrieved on: 
Mercredi, mars 27, 2024
MSD, Research, Conference call, Conference, Head, AstraZeneca, E7, Patient, Merck & Co., Tumor microenvironment, Merck, News, R&I, Cancer, Virus, MD, E6, Lung cancer, AACR, NEC, European Journal, HPV16, Euronext Paris, De novo, Immune system, ASCO, Safety, Poster, Potyvirus, Pharmaceutical industry

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.

Key Points: 
  • Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
  • “During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
  • As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
  • In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.